Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
$ E, [- h' P+ }7 Y1 [& K' z2 |- iNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ' j& `8 @" ^# a9 \
+ Author Affiliations/ D1 }. B4 {, W1 ?$ Q$ n% @
( U9 o$ m/ b; N H
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
9 J' f& J% c1 l1 {% f& ^8 o2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan , B5 \; z2 G7 z
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan $ |) d* L, ^0 e; {0 n
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) K: Q8 ^+ l) e( m1 O9 M
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ( p5 T, u. T8 b% z
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 4 }5 J. B0 k1 L1 P' ]/ G! }7 T1 D
7Kinki University School of Medicine, Osaka 589-8511, Japan
% M M y3 X+ D, b$ q8Izumi Municipal Hospital, Osaka 594-0071, Japan
8 N" G! k, b- n9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
5 l4 p7 B% T7 k7 @$ ^. }1 O. aCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 9 @- Z/ s, H1 o
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ) z5 c/ ?0 I: E: L& d$ ^& a
" O* T% k* }2 _* G% F! [ b |